These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 4041368)

  • 1. Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma.
    Simonsson B; Källander CF; Brenning G; Killander A; Ahre A; Gronowitz JS
    Br J Haematol; 1985 Oct; 61(2):215-24. PubMed ID: 4041368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia.
    Källander CF; Simonsson B; Hagberg H; Gronowitz JS
    Cancer; 1984 Dec; 54(11):2450-5. PubMed ID: 6498737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum deoxythymidine kinase: no help in the diagnosis and prognosis of monoclonal gammopathy.
    Bäck H; Jagenburg R; Rödjer S; Westin J
    Br J Haematol; 1993 Aug; 84(4):746-8. PubMed ID: 8217837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
    Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
    Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum thymidine kinase in multiple myeloma: II. Relation to disease activity and stage].
    Scudla V; Papajík T; Bacovský J; Budíková M; Klímová D
    Vnitr Lek; 1994 Mar; 40(3):157-62. PubMed ID: 8184567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
    Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
    Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma.
    Luoni R; Ucci G; Riccardi A; Gobbi P; Avato FM; Vignale C; Ascari E
    Cancer; 1992 Mar; 69(6):1368-72. PubMed ID: 1540874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers.
    Gronowitz JS; Steinholtz L; Källander CF; Hagberg H; Bergh J
    Cancer; 1986 Jul; 58(1):111-8. PubMed ID: 3011236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum thymidine kinase activity of various cancer and HBV positive liver diseases].
    Torizumi K; Aibata H; Kiji S; Ohta K; Okamoto Y; Ohshiro I; Hirose T
    Radioisotopes; 1987 Mar; 36(3):133-6. PubMed ID: 3602478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical markers in multiple myeloma: a multivariate analysis.
    Simonsson B; Källander CF; Brenning G; Killander A; Gronowitz JS; Bergström R
    Br J Haematol; 1988 May; 69(1):47-53. PubMed ID: 3289607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The enzymatic character of myeloma cell].
    Yoshikawa O; Furuya T; Toyama K
    Nihon Rinsho; 1995 Mar; 53(3):598-602. PubMed ID: 7699891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.
    Gronowitz JS; Hagberg H; Källander CF; Simonsson B
    Br J Cancer; 1983 Apr; 47(4):487-95. PubMed ID: 6849793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An in-house assay for serum deoxythymidine kinase.
    Seah LH; Ton SH; Cheong SK; Hamidah NH
    Malays J Pathol; 1991 Dec; 13(2):109-13. PubMed ID: 1823092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum thymidine kinase in vitamin B12 deficiency.
    Hagberg H; Gronowitz S; Killander A; Källander C
    Scand J Haematol; 1984 Jan; 32(1):41-5. PubMed ID: 6695149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum deoxythymidine kinase in hematological malignancy].
    Naito K; Yamada K
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3221-6. PubMed ID: 3196040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.
    Hallek M; Emmerich B; Strohmeyer S; Busch R; Reichle A; Senekowitsch R
    Klin Wochenschr; 1988 Aug; 66(16):718-23. PubMed ID: 3172680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum deoxythymidine kinase activity in adult T-cell leukemia].
    Kagimoto T; Oda T; Nakakuma H; Kawaguchi T; Hidaka M; Horikawa K; Matsuzaki H; Takatsuki K
    Gan To Kagaku Ryoho; 1991 Jan; 18(1):63-7. PubMed ID: 1987901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.